Psychiatry research · 2026
Medication adherence following pharmacogenomic testing in patients with major depressive disorder.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Del Tredici Andria, Johnson Holly L, DeHart W Brady, Gutin Alexander, Johansen Taber Katherine, Morin Pamela, Becker Laura, Chawla Devika, Nierenberg Andrew A
Аннотация
OBJECTIVE: Approximately 50% of patients with major depressive disorder (MDD) prematurely discontinue their antidepressant medication within 6 months, increasing risk of relapse. Pharmacogenomic (PGx) testing may improve medication adherence by informing treatment based on gene-drug interactions (GDI). Here, we evaluated whether PGx informed treatmentimproved medication adherence in MDD patients.
METHODS: This was an observational, retrospective claims study of adult MDD patients who received a weighted multi-gene PGx test between 1 Jan 2015 and 30 September 2021 and switched medication. PGx results were linked with de-identified administrative claims data from the Optum Labs Data Warehouse. The PGx test report organized psychiatric medications into three categories: no known GDI (congruent), moderate GDI (congruent), and significant GDI (incongruent). Patients were assigned to the following groups based on the medication with the worst congruency 90 days pre- and post-PGx testing: incongruent-to-congruent, no-change-in-congruency, and congruent-to-incongruent. Medication adherence (proportion of days covered [PDC]) and discontinuation (a ≥ 45-day gap in medication fills) were assessed using pharmacy fill data during the 180 days following the date of medication switch (index date).
RESULTS: Among 6224 patients with PGx testing, those in the incongruent-to-congruent group had the highest adherence (mean PDC 0.65, SD 0.33), compared to the congruent-to-incongruent (mean PDC 0.58, SD 0.34) (p < 0.05) and no-change-in-congruency groups (mean PDC 0.61, SD 0.34) (p < 0.05). The incongruent-to-congruent group also had the lowest discontinuation rate (46%) compared to the congruent-to-incongruent (55%) (p < 0.05) and no-change-in-congruency groups (50%) (p < 0.05).
CONCLUSIONS: Using PGx informed medication selection can improve medication adherence and reduce discontinuation among MDD patients.
METHODS: This was an observational, retrospective claims study of adult MDD patients who received a weighted multi-gene PGx test between 1 Jan 2015 and 30 September 2021 and switched medication. PGx results were linked with de-identified administrative claims data from the Optum Labs Data Warehouse. The PGx test report organized psychiatric medications into three categories: no known GDI (congruent), moderate GDI (congruent), and significant GDI (incongruent). Patients were assigned to the following groups based on the medication with the worst congruency 90 days pre- and post-PGx testing: incongruent-to-congruent, no-change-in-congruency, and congruent-to-incongruent. Medication adherence (proportion of days covered [PDC]) and discontinuation (a ≥ 45-day gap in medication fills) were assessed using pharmacy fill data during the 180 days following the date of medication switch (index date).
RESULTS: Among 6224 patients with PGx testing, those in the incongruent-to-congruent group had the highest adherence (mean PDC 0.65, SD 0.33), compared to the congruent-to-incongruent (mean PDC 0.58, SD 0.34) (p < 0.05) and no-change-in-congruency groups (mean PDC 0.61, SD 0.34) (p < 0.05). The incongruent-to-congruent group also had the lowest discontinuation rate (46%) compared to the congruent-to-incongruent (55%) (p < 0.05) and no-change-in-congruency groups (50%) (p < 0.05).
CONCLUSIONS: Using PGx informed medication selection can improve medication adherence and reduce discontinuation among MDD patients.